Put Options

18 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$22.0 - $69.71 $343,200 - $1.09 Million
15,600 Added 37.32%
57,400 $3.85 Million
Q1 2024

May 15, 2024

BUY
$25.72 - $29.94 $797,320 - $928,140
31,000 Added 287.04%
41,800 $1.13 Million
Q4 2023

Feb 14, 2024

SELL
$23.42 - $31.74 $133,494 - $180,918
-5,700 Reduced 34.55%
10,800 $334,000
Q3 2023

Nov 15, 2023

BUY
$19.86 - $26.93 $327,690 - $444,345
16,500 New
16,500 $416,000
Q2 2021

Aug 06, 2021

SELL
$24.17 - $36.01 $210,279 - $313,287
-8,700 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$32.28 - $44.3 $16,140 - $22,150
500 Added 6.1%
8,700 $281,000
Q4 2020

Feb 12, 2021

BUY
$31.45 - $40.54 $257,890 - $332,428
8,200 New
8,200 $279,000
Q2 2020

Aug 13, 2020

SELL
$14.11 - $29.42 $196,129 - $408,938
-13,900 Closed
0 $0
Q1 2020

May 11, 2020

SELL
$13.63 - $33.98 $70,876 - $176,695
-5,200 Reduced 27.23%
13,900 $238,000
Q4 2019

Feb 12, 2020

BUY
$16.12 - $24.98 $16,120 - $24,980
1,000 Added 5.52%
19,100 $448,000
Q3 2019

Nov 14, 2019

SELL
$15.49 - $25.78 $4,647 - $7,734
-300 Reduced 1.63%
18,100 $331,000
Q2 2019

Aug 20, 2019

SELL
$23.0 - $32.19 $57,500 - $80,475
-2,500 Reduced 11.96%
18,400 $471,000
Q1 2019

May 15, 2019

BUY
$13.91 - $31.15 $290,719 - $651,035
20,900 New
20,900 $608,000
Q4 2018

Feb 14, 2019

SELL
$11.6 - $18.7 $259,840 - $418,880
-22,400 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$18.95 - $28.08 $371,420 - $550,368
-19,600 Reduced 46.67%
22,400 $453,000
Q1 2018

May 15, 2018

BUY
$21.69 - $32.99 $455,490 - $692,790
21,000 Added 100.0%
42,000 $946,000
Q4 2017

Feb 14, 2018

SELL
$26.43 - $31.78 $1.5 Million - $1.8 Million
-56,700 Reduced 72.97%
21,000 $655,000
Q3 2017

Nov 15, 2017

BUY
$11.61 - $31.21 $902,097 - $2.43 Million
77,700
77,700 $2.43 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.82B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.